ClinicalTrials.gg
Active, not recruitingNCT05783596Updated Sep 25, 2026

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

A Phase 2 interventional study of Obinutuzumab and Glofitamab in Follicular Lymphoma, Marginal Zone Lymphoma and Indolent Non-hodgkin Lymphoma, sponsored by Reid Merryman, MD. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Reid Merryman, MD · Phase 2, Interventional, and Treatment

How we know

Updated Sep 25, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing obinutuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 1 of them phase 3. obinutuzumab · Lymphoma, Follicular.

Enrollment
17th of 30
47 · median 49
Started
2023
the only one that year
Phase 2
18 of 30
7 open now
Primary completion
2026-05
later than 6 of 14 live
Registered
26th of 30
by date

Among the 30 studies testing obinutuzumab in Lymphoma, Follicular, this one is the 17th largest by enrollment, is the only one that started in 2023, is one of 18 in phase 2, reaches primary completion later than 6 of the 14 other live ones, and was the 26th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

8 of the 30 studies testing obinutuzumab in Lymphoma, Follicular are open now, in 4 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing obinutuzumab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma.

The names of the study drugs involved in this study are:

  • Glofitamab (a type of immunotherapy)
  • Obinutuzumab (a type of immunotherapy)
Read the detailed description

This is an open-label, multicenter, phase II study to evaluate the efficacy and safety of obinutuzumab and glofitamab for patients with untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). Obinutuzumab and Glofitamab use the immune system to target and attack cancer cells.

The research study procedures include screening for eligibility, study treatment visits, bone marrow biopsies, blood tests, Computerized Tomography (CT) scans, and Positron Emission Tomography (PET) scans.

The U.S. Food and Drug Administration (FDA) has not approved glofitamab as a treatment for any disease.

The U.S. FDA has approved obinutuzumab in combination with chemotherapy for patients with follicular lymphoma.

Participants will receive study treatment for approximately 9 months and will be followed for 10 years.

It is expected that about 45-50 people will take part in this research study.

Genentech and Roche are supporting this research study by providing the study drugs, glofitamab and obinutuzumab, and funding for the study.

03

Conditions studied

  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Indolent Non-hodgkin Lymphoma

Keywords

  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Indolent Non-hodgkin Lymphoma
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of either FL (grade 1-3A) or MZL (any subtype) with review of the diagnostic pathology specimen at one of the participating institutions. Patients with active histologic transformation are excluded.
  • No prior systemic therapy for FL or MZL. Prior treatment with radiation therapy or short course is allowed.
  • Meets at least one criterion to begin treatment based on the modified GELF criteria:

    • Symptomatic adenopathy
    • Organ function impairment due to disease involvement, including cytopenias due to marrow involvement (WBC \<1.5x109/L; [ANC] \<1.0x109/L, \<10g/dL; or \<100x109/L)
    • Constitutional symptoms
    • Maximum diameter of disease > 7cm
    • >3 nodal sites of involvement
    • Risk of local compressive symptoms
    • Splenomegaly (craniocaudal diameter > 16cm on CT imaging)
    • pleural or peritoneal effusion
    • Leukemic phase (>5x109/L circulating malignant cells)
    • Rapid generalized disease progression
    • Renal infiltration
    • Bone lesions
  • Patients cannot be in need of urgent cytoreductive chemotherapy in the opinion of the treating investigator.
  • (ECOG) performance status of 0-2. (Appendix A)
  • Age ≥18 years.
  • Adequate hematologic and organ function:

    • Absolute neutrophil count > 1.0x109/L unless due to marrow involvement by lymphoma in which case ANC must be >0.5x109/L
    • Platelets > 75 x109/L, unless due to marrow involvement by lymphoma, in which case platelets must be >50 x109/L
    • > 40ml/min (by Cockcroft-Gault Formula)
    • Total \< 1.5 X , unless Gilbert syndrome, in which case direct bilirubin must be \< 1.5 x ULN
    • /ALT \< 2.5 X ULN, unless documented liver involvement by lymphoma, in which case AST/ALT must be \<5 x ULN
  • Ability to understand and the willingness to sign a written document.
  • Willingness to provide a pre-treatment tumor sample by core needle or excisional surgical . A fresh biopsy is strongly encouraged, but an archival sample is acceptable if the following provisions are met: 1) availability of a tumor-containing formalin-fixed, paraffin-embedded (FFPE) tissue block, 2) if the tumor containing FFPE tissue block cannot be provided in total, sections from this block should be provided that are freshly cut and mounted on positively-charged glass slides (SuperFrost Plus are recommended). Preferably, 25 slides should be provided; if not possible, a minimum of 15 slides is required. Exceptions to this criterion may be made with approval of the sponsor-investigator.
  • Willingness to remain abstinent or to use two effective methods that result in a failure rate of \<1% per year from screening until: (a) at least 3 months after pre-treatment with obinutuzumab or 2 months after the last dose of glofitamab, whichever is longer, if the patient is a male or (b) until at least 18 months after pre-treatment with obinutuzumab or 2 months after the last dose of glofitamab, whichever is longer, if patient is a female. Examples of contraceptive methods with a failure rate of \<1% per year include:

    • Tubal ligation, male sterilization, hormonal implants, established proper use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
    • Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate of \<1% per year. Barrier methods must always be supplemented with the use of a spermicide.

Exclusion criteria

Exclusion Criteria:

  • Patients who require systemic therapy for an ongoing medical condition will be excluded. For , patients receiving a prednisone dose of >10 mg daily (or equivalent) will not be eligible. A short course of steroids (up to 14 days, not exceeding 40 mg dexamethasone or equivalent in a single day) for symptom palliation is allowed, in which case patients should be off steroids at least 7 days prior to treatment start.
  • Patients with bulky cervical adenopathy that is 1) compressing the upper airway or 2) in close proximity to the upper airway and could result in airway compression during a tumor flare event).
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy unless in consultation with an allergy specialist they are deemed eligible for retreatment with desensitization.
  • Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia).
  • Patients with known infection or or C infection. Testing for HIV is optional. Testing for hepatitis B and C is mandatory. Patients with hepatitis B core Ab positivity but negative surface antigen and negative viral load may be enrolled if they can be treated with a prophylactic agent (e.g., entecavir); patients with seropositivity who have a negative viral load can also be enrolled.
  • Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
  • Prior history of another (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for at least 2 years. Patients with prostate cancer (Gleason score 6-7) are allowed if PSA is less than 1 ng/mL.
  • Patients should not have received immunization with lives or within one week of study entry or during study period.
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study or limit adherence to study requirements.
  • Patients with any one of the following currently on or in the previous 6 months will be excluded: myocardial infarction, congenital long syndrome, torsade de pointes, unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident.
  • Patients with Class III or IV heart failure.
  • Inability to comply with protocol mandated hospitalizations and restrictions
  • Patients who are pregnant, breast-feeding, or intending to become pregnant during the study.
  • Prior solid organ or stem cell transplantation
  • History of known or suspected hemophagocytic lymphohistiocytosis (HLH).
  • History of disease, including but not limited to myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis • Patients with a remote history of, or well controlled, autoimmune disease may be eligible to enroll after consultation with the study PI.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Obinutuzumab + Glofitamab for Follicular Lymphoma

    Participants will undergo study procedures as outlined: * Imaging scans (CT or PET) at screening and after cycles 3, 7, and 12 of treatment. * Bone marrow biopsy at baseline. * Cycle 1 * Days -21, -14, -7, 0 of 36 day cycle: Predetermined dose of Obinutuzumab. * Days 1 and 8 of 36 day cycle: Predetermined dose of Glofitamab. (First dose will be administered in the hospital.) * Cycles 2 - 12: o Day 1 of 21 day cycle: Predetermined dose of Glofitamab. * Bone marrow biopsy within 2 weeks of end of treatment. * Imaging scans (CT or PET) at 12, 18, and 24 months after treatment initiation. * Follow up visits up to 5 years after treatment completion.

    Drug: Obinutuzumab · Drug: Glofitamab

  • Experimental
    Obinutuzumab + Glofitamab for Marginal Zone Lymphoma

    Participants will undergo study procedures as outlined: * Imaging scans (CT or PET) at screening and after cycles 3, 7, and 12 of treatment. * Bone marrow biopsy at baseline. * Cycle 1 * Days -21, -14, -7, 0 of 36 day cycle: Predetermined dose of Obinutuzumab. * Days 1 and 8 of 36 day cycle: Predetermined dose of Glofitamab. (First dose will be administered in the hospital.) * Cycles 2 - 12: o Day 1 of 21 day cycle: Predetermined dose of Glofitamab. * Bone marrow biopsy within 2 weeks of end of treatment. * Imaging scans (CT or PET) at 12, 18, and 24 months after treatment initiation. * Follow up visits up to 5 years after treatment completion.

    Drug: Obinutuzumab · Drug: Glofitamab

Interventions

  • Humanized glycoengineered type II anti-CD20 monoclonal antibody, via IV infusion.

    Also known as: RO5072759, GA101, GAZYVA, GAZYVARO

  • T-cell bispecific humanized monoclonal antibody, via IV infusion.

    Also known as: RO7082859

06

What researchers measure

Primary outcomes

  1. End of Treatment (EOT) Complete Metabolic Response (CMR) Rate

    EOT CMR rate defined as the proportion of participants achieving CR per PET/CT Lugano 2014 criteria (protocol appendix B) at the EOT assessment: PET-CT, score 1, 2, or 3 with or without a residual mass on a 5-point scale (5PS).

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days

Secondary outcomes

  1. Best Partial Metabolic Response (PMR) Rate

    Best PMR rate defined as the proportion of participants achieving PR per Lugano 2014 criteria (protocol appendix B) ever on treatment: PET-CT Score 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size or on CT, ≥ 50% decrease in SPD of up to 6 target measurable nodes and extranodal sites; no increase in non-measured lesions; spleen if enlarged must have regressed by \>50% in length beyond normal.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days

  2. Best Complete Metabolic Response (CMR) Rate

    Best CMR rate defined as the proportion of participants achieving CR per Lugano 2014 criteria (protocol appendix B) ever on treatment.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days

  3. Best Objective Metabolic Response (OMR) Rate

    Best OMR rate defined as the proportion of participants achieving CR or partial response (PR) per Lugano 2014 criteria (protocol appendix B) ever on treatment.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days

  4. EOT Partial Metabolic Response (PMR) Rate

    EOT PMR rate defined as the proportion of participants achieving PR per PET/CT Lugano 2014 criteria (protocol appendix B) at the EOT assessment: PET-CT Score 4 or 5 with reduced uptake compared with baseline and residual mass(es).

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days

  5. EOT Objective Metabolic Response (OMR) Rate

    EOT OMR rate defined as the proportion of participants achieving CR or partial response (PR) per PET/CT Lugano 2014 criteria (protocol appendix B) at the EOT assessment.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days

  6. 2-year Duration of Response (DOR)

    2-year DOR is a probability estimated using the Kaplan Meier method; DOR is defined as the time measurement criteria are met for CR or PR (whichever is first recorded) per Lugano 2014 criteria (protocol Appendix B) until the first date that recurrent or progressive disease is objectively documented, or death due to any cause. CR and PR participants without events reported are censored at the last disease evaluation.

    Time frame: 2 years

  7. 2-year Duration of Complete Response (DOCR)

    2-year DOCR is a probability estimated using the Kaplan Meier method; DOCR is defined as the time measurement criteria are met for CR per Lugano 2014 criteria (protocol Appendix B) until the first date that recurrent or progressive disease is objectively documented, or death due to any cause. CR participants without events reported are censored at the last disease evaluation.

    Time frame: 2 years

  8. 2-year Progression-free Survival (PFS)

    2-year PFS is a probability estimated using the Kaplan Meier method; PFS is defined as the duration of time from study entry to documented disease progression (PD) or death. PD defined by Lugano 2014 criteria (protocol Appendix B).

    Time frame: 2 years

  9. 2-year Time-to-Next Treatment (TTNT)

    2-y TTNT is a probability estimated using the Kaplan Meier method; TTNT is defined as the duration of time from the first dose of treatment until the time of initiation of new therapy, or censored at the date of last contact.

    Time frame: 2 years

  10. 2-year Overall Survival (OS)

    2-year OS is a probability estimated using the Kaplan-Meier method; OS is defined as the time from study entry to death, or censored at date last known alive.

    Time frame: 2 years

  11. Incidence of Histological Transformation

    Histological transformation was defined as participants who have a biopsy showing diffuse large B-cell lymphoma (DLBCL). Incidence is the number of participants with histological transformation during or after treatment.

    Time frame: up to 10 years

  12. Number of Participants with Cytokine Release Syndrome (CRS) by Grade

    All grade CRS AEs regardless of attribution based on American Society of Transplantation and Cellular Therapy \[ASTCT\] Consensus grading as reported on case report forms are counted and maximum grade tabulated. Incidence by grade is then tabulated as the number of participants ever experiencing maximum grade during the time of observation.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days + 30 days

  13. Grade 3-5 Treatment-Related CRS Rate

    All grade 3-5 CRS AEs with attribution of probably, possibly or definitely-related to treatment based on American Society of Transplantation and Cellular Therapy \[ASTCT\] Consensus grading as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3-5 CRS AE of any type during the time of observation.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days + 30 days

  14. Number of Participants with Neurotoxicity by Grade

    All grade neurotoxicity AEs regardless of attribution based on CTCAEv5 as reported on case report forms are counted and maximum grade tabulated. Incidence by grade is then tabulated as the number of participants ever experiencing maximum grade during the time of observation.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days + 30 days

  15. Grade 3-5 Treatment-Related Neurotoxicity Rate

    All grade 3-5 neurotoxicity AEs with attribution of probably, possibly or definitely-related to treatment based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3-5 neurotoxicity AE of any type during the time of observation.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days + 30 days

  16. Grade 3-5 Toxicity Rate

    All grade 3-5 AEs regardless of attribution based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one grade 3-5 AE of any type during the time of observation.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days + 30 days

  17. Grade 3-5 Treatment-Related Toxicity Rate

    All grade 3-5 AEs with attribution of probably, possibly or definitely-related to treatment based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3-5 AE of any type during the time of observation.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days + 30 days

  18. Grade 2-5 Treatment-Related Toxicity Rate

    All grade 2-5 AEs with attribution of probably, possibly or definitely-related to treatment based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 2-5 AE of any type during the time of observation.

    Time frame: (Cycle 1 = 36 days, cycle 2 - 12 = 21 days), up to 267 days + 30 days

07

Study locations

4 sites
08

References and documents

Publications

  • Sharp J, Shana'ah AY, Voorhees TJ, Bond DA, Sawalha Y, Sigmund A, Hanel W, Sehgal L, Alinari L, Baiocchi R, Maddocks K, Jones D, Christian B, Epperla N. Resistance Mechanism for Zanubrutinib in Marginal Zone Lymphoma. J Natl Compr Canc Netw. 2025 Jun 23;23(7):e257045. doi: 10.6004/jnccn.2025.7045. PubMed 40550489 ↗

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in May 2026, 34 months.

Of 151 non-industry phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 110. This study's 34 months is below that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → May 2026, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Mar 24, 2023
StartActual
Jul 18, 2023
Primary completionActual
May 27, 2026was Aug 2026
CompletionEst.
Aug 2029
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2026→May 27, 2026 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Primary completion Aug 2026→May 27, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05783596
Lead sponsor
Reid Merryman, MD
Collaborators
Genentech, Inc.
Responsible party
Reid Merryman, MD (Principal Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Mar 24, 2023
Start date
Jul 18, 2023
Primary completion
May 27, 2026
Completion
Aug 2029 (estimated)
Last update
Sep 25, 2026

Study contacts

Reid Merryman, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Obinutuzumab · Glofitamab

Start the discussion